Early phase I data demonstrated the safety and efficacy of ivosidenib and enasidenib with intensive chemotherapy and as maintenance therapy in newly diagnosed IDH1/IDH2-mutated AML, but these agents are not FDA approved in the maintenance setting [48]. Here, IDH2 is linked to acute myeloid leukemia.